{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+Psoriasis&page=2", "query": { "condition": "Moderate Psoriasis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+Psoriasis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T20:13:12.019Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04713592", "title": "Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Placebo for Risankizumab", "type": "DRUG" }, { "name": "Risankizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2021-02-26", "completion_date": "2023-04-20", "has_results": true, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-07-24T20:13:12.019Z", "location_count": 34, "location_summary": "Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04713592" }, { "nct_id": "NCT01018134", "title": "Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Desoximetasone 0.05% once daily", "type": "DRUG" }, { "name": "Desoximetasone 0.05% twice daily", "type": "DRUG" }, { "name": "Desoximetasone 0.25% once daily", "type": "DRUG" }, { "name": "Vehicle once daily", "type": "DRUG" }, { "name": "Vehicle twice daily", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2009-11", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2014-08-05", "last_synced_at": "2026-07-24T20:13:12.019Z", "location_count": 7, "location_summary": "Miami, Florida • Martinez, Georgia • Olathe, Kansas + 4 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Martinez", "state": "Georgia" }, { "city": "Olathe", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT01018134" }, { "nct_id": "NCT02718898", "title": "A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Genital Psoriasis", "Psoriasis" ], "interventions": [ { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2016-04", "completion_date": "2018-02-21", "has_results": true, "last_update_posted_date": "2019-09-16", "last_synced_at": "2026-07-24T20:13:12.019Z", "location_count": 13, "location_summary": "Santa Ana, California • Santa Monica, California • Tampa, Florida + 9 more", "locations": [ { "city": "Santa Ana", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02718898" }, { "nct_id": "NCT06220604", "title": "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "JNJ-77242113", "type": "DRUG" }, { "name": "JNJ-77242113 Matching Placebo", "type": "DRUG" }, { "name": "Deucravacitinib", "type": "DRUG" }, { "name": "Deucravacitinib Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 731, "start_date": "2024-03-09", "completion_date": "2027-09-20", "has_results": true, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-07-24T20:13:12.019Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Encinitas, California • Encino, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06220604" }, { "nct_id": "NCT02748863", "title": "Study of Secukinumab With 2 mL Pre-filled Syringes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Secukinumab 2 mL form", "type": "DRUG" }, { "name": "Secukinumab 1 mL form", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 214, "start_date": "2016-12-12", "completion_date": "2018-06-08", "has_results": true, "last_update_posted_date": "2019-07-15", "last_synced_at": "2026-07-24T20:13:12.019Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Fountain Valley, California • Fremont, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02748863" }, { "nct_id": "NCT02931838", "title": "Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "BMS-986165", "type": "DRUG" }, { "name": "Placebo for BMS-986165", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 268, "start_date": "2016-11-15", "completion_date": "2017-11-16", "has_results": true, "last_update_posted_date": "2020-11-27", "last_synced_at": "2026-07-24T20:13:12.019Z", "location_count": 16, "location_summary": "Irvine, California • San Diego, California • Ocala, Florida + 13 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Macon", "state": "Georgia" }, { "city": "Champaign", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02931838" }, { "nct_id": "NCT04102007", "title": "A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2019-11-12", "completion_date": "2022-11-07", "has_results": true, "last_update_posted_date": "2023-11-27", "last_synced_at": "2026-07-24T20:13:12.019Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Hot Springs, Arkansas • North Little Rock, Arkansas + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04102007" }, { "nct_id": "NCT06611163", "title": "A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Genital Psoriasis" ], "interventions": [ { "name": "Tildrakizumab 100 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 206, "start_date": "2025-03-21", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-07-24T20:13:12.019Z", "location_count": 36, "location_summary": "Anaheim, California • Encinitas, California • Encino, California + 29 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06611163" }, { "nct_id": "NCT02387801", "title": "A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Ixekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2015-04", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-07-24T20:13:12.019Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02387801" }, { "nct_id": "NCT02826603", "title": "Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1114, "start_date": "2016-06-22", "completion_date": "2018-07-09", "has_results": true, "last_update_posted_date": "2019-07-09", "last_synced_at": "2026-07-24T20:13:12.019Z", "location_count": 123, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 103 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02826603" } ] }